Germline CDK12 variants in aggressive prostate cancer
Authors:
- Sofie H. TolmeijerSTSofie H. Tolmeijer
- Corinne Maurice-DrorCMCorinne Maurice-Dror
- Shahneen SandhuShahneen Sandhu
- Claire M. de la CalleCCClaire M. de la Calle
- Christian KollmannsbergerCKChristian Kollmannsberger
- Mohamed AdilMAMohamed Adil
- Catherine K. WangCWCatherine K. Wang
- Andrew J. MurthaAMAndrew J. Murtha
- Gráinne DonnellanGDGráinne Donnellan
- Nielka P. van ErpNENielka P. van Erp
- Niven MehraNMNiven Mehra
- Michael S. HofmanMHMichael S. Hofman
- 2 July 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF8
Abstract
CDK12 mutations occur in 2-7% of metastatic prostate cancers (mPCa) and are considered to be exclusively somatic. Here, we identified five patients with mPCa (ages 44-62) harboring germline CDK12 truncating variants among 4,535 tested (0.1%). All had CDK12-driven cancers defined by an additional somatic CDK12 variant and the CDK12-specific hallmark genomic instability signature characterized by hundreds of tandem duplications. Two patients had multiple independent CDK12-driven tumors with distinct secondary somatic CDK12 variants. Germline CDK12 truncating variants were enriched in mPCa compared to gnomAD V4.1.0 controls (n=807,162; odds ratio 11.4, 95% CI 3.6-27.8) and V2.1.1 non-cancer controls (n=134,187; odds ratio 29.6; 95% CI 6.8-28.6). Family history revealed multiple related individuals with prostate or ovarian cancer, and germline variant inheritance was confirmed in the two tested pedigrees. Our data suggest that germline CDK12 truncating variants are a rare driver of lethal mPCa.Keywords
Funding Information
- Prostate Cancer Foundation
- Terry Fox Research Institute
- Canadian Cancer Society Research Institute
- Canadian Institutes of Health Research
- Michael Smith Health Research BC
- Pacific Northwest Prostate Cancer SPORE (CA097186)
- Congressionally Directed Medical Research Programs (W81XWH-17-2-0043)
- National Institutes of Health (CA015704)
- National Institutes of Health (CA280056)
- Pacific Northwest Prostate Cancer SPORE (P30CA015704)
- Congressionally Directed Medical Research Programs (PC230420)
- Australian Cancer Research Foundation
- National Health and Medical Research Council
- Peter MacCallum Foundation
- BC Cancer Foundation
- Genome Canada
- Genome British Columbia
- Canadian Cancer Society (707213)
- Canadian Cancer Society (706667)
- Pfizer
- AstraZeneca
- Bayer in The US
- Roche